Loading...
LivaNova Q1 2025 Earnings Report
LivaNova reported strong first-quarter 2025 results, with significant revenue growth and improved profitability, and updated its full-year 2025 guidance.
Key Takeaways
LivaNova PLC announced robust first-quarter 2025 results, with revenue increasing by 7.4% on a reported basis and 10.4% organically. The company reported a GAAP diluted loss per share of $6.01 due to a significant environmental liability, but adjusted diluted earnings per share reached $0.88. Strong performance in Cardiopulmonary and Neuromodulation segments, along with key regulatory milestones for the aura6000™ System, contributed to the positive quarter.
First-quarter revenue increased 7.4% reported, 8.9% constant-currency, and 10.4% organic, driven by strong demand and product rollout.
Adjusted diluted earnings per share was $0.88, demonstrating operational efficiency despite a significant environmental liability.
Completed PMA submission for the aura6000™ System and announced positive 12-month OSPREY trial data, highlighting progress in obstructive sleep apnea treatment.
Raised full-year 2025 revenue growth guidance to 6.0%-7.0% constant-currency and 7.0%-8.0% organic, reflecting stronger operational performance expectations.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
LivaNova updated its full-year 2025 guidance, raising revenue growth expectations and revising adjusted diluted earnings per share to incorporate the SNIA decision and applicable tariffs, while maintaining free cash flow projections.
Positive Outlook
- Full-year 2025 revenue growth range raised to 6.0%-7.0% on a constant-currency basis (up from 5.0%-6.0%).
- Full-year 2025 organic revenue growth range raised to 7.0%-8.0% (up from 6.0%-7.0%).
- Foreign currency expected to be a smaller headwind, ranging from 0.0%-1.0% (down from 1.5%-2.0%).
- Revised adjusted diluted earnings per share range of $3.60-$3.70 incorporates stronger operational performance expectations.
- Adjusted free cash flow expected to be in the range of $135 million to $155 million, consistent with prior guidance.
Challenges Ahead
- Revised full-year 2025 adjusted diluted earnings per share range ($3.60-$3.70) now incorporates the impact of the SNIA decision.
- The SNIA decision and currently applicable tariffs are expected to reduce adjusted diluted earnings per share by approximately $0.20 in 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...